

INDEX TO VOLUME 2

AUTHORS

- APELO, R., 391
 AVERKIN, E., 381
 BONDANI, A., 259
 BRINSON, A., 29
 BROWN, W., 381
 CHENAULT, C.B., 339
 CHENG, T.Y., 275
 CHEZ, R.A., 127
 COUTINHO, E.M., 313
 CROXATTO, H.B., 179
 CUADROS, A., 29
 DASGUPTA, P.R., 59
 DOWNING, B., 113
 DUFFY, T.J., 289
 EL-SAHWI, S., 1
 FILHO, J.A., 313
 FUETEALBA, B., 179
 GAGNE, W.E., 381
 GOLDZIEHER, J.W., 225, 283 & 323
 GOPALCHARI, R., 199
 GORDOVSKY, J., 283
 HICKS, J.J., 259
 HILL, R., 381
 HUTCHINSON, D.L., 127
 IYER, R.N., 199
 JOSHI, S.G., 137, 339, 353
 KAMBOJ, V.P., 199
 KAR, A.B., 59, 199
 KLEBER, J.W., 225
 KRAEMER, D.C., 339, 353
 KUTNER, S.J., 289
 LAUMAS, K.R., 331
 LAUMAS, V., 331
 LEE, C.H., 275
 LEETON, J., 113
 LEWIS, R.B., 249
 LEWIT, S., 47
 LONGENECKER, D.E., 401
 MALKANI, P.K., 331
 MANDEL, J.E., 323
 MARTINEZ-MANAUTOU, J., 259
 MARTINEZ-ZEDILLO, G., 259
 MATHEWS, J., 113
 MATTHIJSEN, C., 323
 MATTOS, C.E.R., 313
 MAQUEO, M.T., 283
 MISHELL, D.R., JR., 99
 MORRIS, J.M., 85
 MOSES, L.E., 225
 MOYER, D.L., 1
 NEISULER, R.F., 99
 PANDE, J.K., 59
 PRASAD, M.R.N., 165
 RAJALAKSHMI, M., 165
 RATHMACHER, R.P., 225
 RICE-WRAY, E., 283
 ROSADO, A., 259
 SANT'ANNA, A.R.S., 313
 SANWAL, P.C., 59
 SEGRE, E., 381
 SEN, A., 59
 SILVA, M.C., 313
 SINGH, S.P., 165
 SOLAL, R., 407
 SRIVASTAVA, A.K., 59
 STURTEVANT, F.M., 187 & 193
 SUNDARAM, K., 29
 TATUM, H.J., 313
 VELOSO, I., 391
 VITTOZ-MEYNARD, Y., 407
 WAIT, R.B., 187 & 193
 WEI, P.Y., 275
 WILLIAMS, L., 113
 WOOD, C., 113
 ZUSPAN, F.P., 249



INDEX TO VOLUME 2

SUBJECT INDEX

- Abortion, therapeutic, 127
 17 α -acetoxy-6-methylpregn-4,6-diene-3,20-dione (Megestrol acetate)
 also (6-methyl-17 α -hydroxy-pregn-4,6-dione-3,20-dione acetate)
 Acid phosphatase, effect of IUBB on, 339
 3-alkyl-2,3-diphenylpropiophenone, derivatives of, 199
 Anti-androgen, cyproterone acetate (rat), 165
 Antifertility agents (rat), derivatives of 3-alkyl-2,3-diphenyl-propiophenone, 199
 Biochemical alterations by Norgestrel (rat), 59
 Biochemical changes by IUBB, 1
 Biochemical changes by IUBB (rat), 137
 Biological effects of IUBB, 1
 Breakthrough bleeding, 283
 Calcium ion, effect on sperm motility, 259
 Cervix, effects on, IUBB, 1
 Chlormadinone acetate, 381
 Chlormadinone acetate, 6-chloro-17 α -hydroxy-pregn-4,6-diene-3,20-dione acetate
 6-chloro-17 α -hydroxy-pregn-4,6-diene-3,20-dione acetate (chlormadinone acetate)
 Combination contraceptive,
 norethindrone and mestranol, 225
 plasma LH and FSH levels, 225
 Congenital anomalies from estrogen administration, 85
 Contraceptive methods, emotional attitudes to, 113
 Cyproterone acetate, 165
 effect on spermatozoa (rat), 165
 Silastic capsule (rat), 165
 Dimethisterone, 187 & 193
 6 α -21-dimethyl-17-ethynyl-17 β -hydroxyandrost-4-en-3-one (Dimethisterone)
 Eggs, effect by IUD (rat), 179
 Emotional attitudes to contraceptive methods, 113
 Endometrial biopsies (monkey), 29
 Endometrial biopsy, 275
 Endometrial sinusoids, 283
 effect of contraceptive steroids, 283
 Endometrium, histologic study, 275
 Enovid, norethynodrel and mestranol, 331
 Estrogenic activity
 in goat milk, 331
 in human milk, 331
 Estrogens, congenital anomalies from, 85

CONTRACEPTION

- 17 α -ethynyl-13 β -ethyl-17 β -hydroxy-4-estren-3-one-norgestrel
 - also, 13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-5(10)-en-20yn-3-one, 59
- Ethinyl estradiol, 187, 193, & 391
- 17-ethynyl-estra-1,3,5(10)-triene-3, 17 β -diol (ethinyl estradiol)
- 17 α -ethynyl-13 β -ethyl-17 β -hydroxy-4-estren-3-one (norgestrel)
- 17 α -ethynyl-17-hydroxy-5(10)-estren-3-one (norethynodrel), 331
- 17-ethynyl-3-methoxy-1,3,5(10)-estratrien-17-ol (mestranol)
- 17 α -ethynyl-19-nor-testosterone (norethindrone)
- Experimental variations, IUBF, 1
- Fear of pregnancy test, 289
- Fertility inhibition by
 - HCG (rabbit), 323
 - placental extract (rabbit), 323
- Foreign body (see IUBF)
 - biochemical changes (rat), 137
 - effect on uterus (rat), 137
- FSH
 - plasma levels, 225
 - women using contraceptives, 225
- General effects of IUBF, 1
- Genital tract, effects on, IUBF, 1
- β -glucuronidase, effect of IUBF on, 339
- HCG, fertility inhibition (rabbit), 323
- High dose estrogen sequential oral contraceptive, 187 & 193
- Histological changes by IUBF, 1
- Hormone shock hypothesis, 289
- 17 α -hydroxy-6 α -methylpregn-4-ene-3,20-dione acetate (medroxyprogesterone acetate)
- Injectable contraceptive
 - medroxyprogesterone acetate, 225
 - plasma LH and FSH levels, 225
- Int. Symp. on Steroids, Gonadotrophins and Reproduction (conference summary), 415
- Intrauterine environment, IUD (rat), 179
- Intrauterine Foreign body (see IUBF), 1
- IUD (see IUBF), 47, 179, 275, 289, 401 & 407
 - analysis of pregnancy outcome, 47
 - broken in situ, 407
 - effect on eggs (rat), 179
 - effect on pregnancy (rat), 401
 - histologic study of endometrium, 275
 - Life Table Method, 47
 - Lippes loop, 407
 - nylon thread (rat), 179
 - plasma LH and FSH levels, 225
 - psychological effects, 289
 - silicone-Shell loop, 99
 - silk suture (rat), 401

- IUFB, 339, 353
 - biochemical changes, 1
 - biological effect of, 1
 - cervix, effect on, 1
 - effect on lysosomal enzymes, 339
 - effect on white blood cells, 339
 - experimental variations, 1
 - general effects of, 1
 - genital tract, effects on, 1
 - histological changes, 1
 - Lippes loop C, 339
 - Margulis Coil, (baboon), 339, 353
 - silk suture (rat), 339, 353
 - species differences, 1
 - sperm, effect on, 1
 - surgical suture (rat), 137
 - systemic effects of, 1
 - uterine flushings
 - baboon, 353
 - rat, 353
 - vagina, effect on, 1
- LH
 - plasma levels, 225
 - women using contraceptives, 225
- Life Table analysis of silicone-Shell loop, 99
- Life Table Method, 187
 - IUD, 47
- Lynestrenol, 17 α -ethynyl-19-norandrost-4-en-17 β -ol, 225
- Megestrol acetate, 29, 313, 331
 - 17 α -acetoxy-6-methylpregn-4,6-diene-3,20-dione
 - progestational activity (monkey), 29
 - Silastic capsule, 313
 - subcutaneous implant, 313
- Microdose
 - cypoterone acetate (rat), 165
 - norgestrel (rat), 59
- Minnesota Multiphasic Personality Inventory (MMPI), 289
 - masculinity-femininity scale (mf), 289
- Norethindrone, 225, 381
 - 17 α -ethynyl-19-nor-testosterone
- Norethynodrel
 - 17 α -ethynyl-17-hydroxy-5(10)-estren-3-one, 331
- Norgestrel, 17 α -ethynyl-13 β -ethyl-17 β -hydroxy-4-estren-3-one, 59, 391
 - biochemical alterations (rat), 59
 - d-norgestrel, contraceptive effect, 391
 - long-term effect (rat), 59

- 19-nor-17 α -pregn-4-en-20-yn-17-ol (lynestrenol), 225
- Oral contraceptive, psychological effects, 289
- Placental extract, fertility inhibition (rabbit), 323
- Polydimethylsiloxan PDS capsule (monkey), 29
- Postcoital antifertility agents, teratogenic effects of, 85
- Postcoital compounds, teratogenicity of (rabbit), 85
- Pregnancy, effect of IUD (rat), 401
- Pregnancy outcome
 - analysis of, IUD, 47
 - with IUD, 47
- Progestational activity of megestrol acetate (monkey), 29
- Progestational potency
 - chlormadinone acetate (beagle), 381
 - norethindrone (beagle), 381
- Sequential contraceptive
 - mestranol and chlormadinone acetate, 225
 - mestranol and lynestrenol, 225
 - plasma LH and FSH levels, 225
- Silastic capsule
 - cyproterone acetate (rat), 165
 - megestrol acetate, 313
 - monkey, in the, 29
 - subcutaneous implant (rat), 165
- Silastic implants (monkey), 29
- Silicone-Shell loop
 - IUD, 99
 - Life Table Analysis, 99
- Species differences, IUFB, 1
- Sperm, effects on, IUFB, 1
- Sperm motility, 259
 - effect by calcium ion, 259
 - effect by zinc ion, 259
- Systemic effects of IUFB, 1
- Teratogenic effects
 - from cytotoxic agents, 85
 - of postcoital antifertility agents, 85
- Teratogenicity of postcoital compounds (rabbit), 85
- Therapeutic abortion, dilemma associated with, 127
- Thromboembolism, 193
- Uterine cavity, determination of contour volume, 249
- Uterine flushings, development of mouse embryo, 353
- Vagina, effects on, IUFB, 1
- White blood cells, effect of IUFB on, 339
- Zinc ion, effect on sperm motility, 259

